Matheus H Dias, Vladyslava Liudkovska, Jasmine Montenegro Navarro, Lisanne Giebel, Julien Champagne, Chrysa Papagianni, Onno B Bleijerveld, Arno Velds, Reuven Agami, René Bernards, Maciej Cieśla
Perturbation of protein phosphorylation represents an attractive approach to cancer treatment. Besides kinase inhibitors, protein phosphatase inhibitors have been shown to have anti-cancer activity. A prime example is the small molecule LB-100, an inhibitor of protein phosphatases 2A/5 (PP2A/PP5), enzymes that affect cellular physiology. LB-100 has proven effective in pre-clinical models in combination with immunotherapy, but the molecular underpinnings of this synergy remain understood poorly. We report here a sensitivity of the mRNA splicing machinery to phosphorylation changes in response to LB-100 in colorectal adenocarcinoma...
April 10, 2024: EMBO Reports